162 related articles for article (PubMed ID: 33369163)
1. Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.
Hamilton JZ; Pires TA; Mitchell JA; Cochran JH; Emmerton KK; Zaval M; Stone IJ; Anderson ME; Jin S; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
ChemMedChem; 2021 Apr; 16(7):1077-1081. PubMed ID: 33369163
[TBL] [Abstract][Full Text] [Related]
2. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
[TBL] [Abstract][Full Text] [Related]
3. Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR
Burke PJ; Hamilton JZ; Pires TA; Lai HWH; Leiske CI; Emmerton KK; Waight AB; Senter PD; Lyon RP; Jeffrey SC
Mol Cancer Ther; 2018 Aug; 17(8):1752-1760. PubMed ID: 29866744
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Biological Evaluation of a Carbamate-Containing Tubulysin Antibody-Drug Conjugate.
Cheng H; Cong Q; Dervin D; Stevens A; Vemuri K; Huber M; Juliano J; Cuison S; Sung J; Passmore D; Chong C; Greenbaum M; Kwok E; Jiang J; Pan C; Rao-Naik C; Rangan V; Kempe T; Tatum A; Deshpande S; Cardarelli P; Vite G; Gangwar S
Bioconjug Chem; 2020 Oct; 31(10):2350-2361. PubMed ID: 32881482
[TBL] [Abstract][Full Text] [Related]
5. Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody-Drug Conjugates.
Burke PJ; Hamilton JZ; Jeffrey SC; Hunter JH; Doronina SO; Okeley NM; Miyamoto JB; Anderson ME; Stone IJ; Ulrich ML; Simmons JK; McKinney EE; Senter PD; Lyon RP
Mol Cancer Ther; 2017 Jan; 16(1):116-123. PubMed ID: 28062707
[TBL] [Abstract][Full Text] [Related]
6. Effect of attachment site on stability of cleavable antibody drug conjugates.
Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
[TBL] [Abstract][Full Text] [Related]
7. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
8. The Recent Developments of ADCs with the Tubulysins as the Payloads.
Xiangrong X; Yao L; Yao A
Mini Rev Med Chem; 2023; 23(18):1797-1805. PubMed ID: 36825713
[TBL] [Abstract][Full Text] [Related]
9. Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.
Staben LR; Yu SF; Chen J; Yan G; Xu Z; Del Rosario G; Lau JT; Liu L; Guo J; Zheng B; Cruz-Chuh JD; Lee BC; Ohri R; Cai W; Zhou H; Kozak KR; Xu K; Lewis Phillips GD; Lu J; Wai J; Polson AG; Pillow TH
ACS Med Chem Lett; 2017 Oct; 8(10):1037-1041. PubMed ID: 29057047
[TBL] [Abstract][Full Text] [Related]
10. Modulation of drug-linker design to enhance in vivo potency of homogeneous antibody-drug conjugates.
Pabst M; McDowell W; Manin A; Kyle A; Camper N; De Juan E; Parekh V; Rudge F; Makwana H; Kantner T; Parekh H; Michelet A; Sheng X; Popa G; Tucker C; Khayrzad F; Pollard D; Kozakowska K; Resende R; Jenkins A; Simoes F; Morris D; Williams P; Badescu G; Baker MP; Bird M; Frigerio M; Godwin A
J Control Release; 2017 May; 253():160-164. PubMed ID: 28257988
[TBL] [Abstract][Full Text] [Related]
11. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of tubulysin analogues.
Courter JR; Hamilton JZ; Hendrick NR; Zaval M; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
Bioorg Med Chem Lett; 2020 Jul; 30(14):127241. PubMed ID: 32527543
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.
Leverett CA; Sukuru SC; Vetelino BC; Musto S; Parris K; Pandit J; Loganzo F; Varghese AH; Bai G; Liu B; Liu D; Hudson S; Doppalapudi VR; Stock J; O'Donnell CJ; Subramanyam C
ACS Med Chem Lett; 2016 Nov; 7(11):999-1004. PubMed ID: 27882198
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of a 5T4 targeting antibody drug conjugate with a novel payload derived from MMAF via C-Lock linker.
Shi B; Wu M; Li Z; Xie Z; Wei X; Fan J; Xu Y; Ding D; Akash SH; Chen S; Cao S
Cancer Med; 2019 Apr; 8(4):1793-1805. PubMed ID: 30843650
[TBL] [Abstract][Full Text] [Related]
17. TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Gymnopoulos M; Betancourt O; Blot V; Fujita R; Galvan D; Lieuw V; Nguyen S; Snedden J; Stewart C; Villicana J; Wojciak J; Wong E; Pardo R; Patel N; D'Hooge F; Vijayakrishnan B; Barry C; Hartley JA; Howard PW; Newman R; Coronella J
Mol Oncol; 2020 Jan; 14(1):54-68. PubMed ID: 31736230
[TBL] [Abstract][Full Text] [Related]
18. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates.
Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J
Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485
[TBL] [Abstract][Full Text] [Related]
19. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer.
Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG
Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436
[TBL] [Abstract][Full Text] [Related]
20. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
